Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-6 ل  6 نتائج ل ""AZD7442""

فلترة النتائج

Publisher : adis
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period.

  • Authors : Hayek S; Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel. .; Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical and Health Sciences, Tel Aviv University, PO Box 39040, Tel Aviv, Israel. .

  • Source: Infectious diseases and therapy [Infect Dis Ther] 2025 Feb; Vol. 14 (2), pp. 433-445. Date of Electronic Publication: 2025 Jan 07.Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.

  • Source: Infectious diseases and therapy [Infect Dis Ther] 2024 Jun; Vol. 13 (6), pp. 1253-1268. Date of Electronic Publication: 2024 May 04.Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups.

  • Authors : Hayek S; Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. .; Innovation Division, Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel. .

  • Source: Infectious diseases and therapy [Infect Dis Ther] 2024 Jun; Vol. 13 (6), pp. 1379-1389. Date of Electronic Publication: 2024 May 10.Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.

  • Authors : Hobbs FDR; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.; NIHR Applied Research Collaboration (ARC) Oxford Thames Valley, Oxford, UK.

  • Source: Infectious diseases and therapy [Infect Dis Ther] 2024 Mar; Vol. 13 (3), pp. 521-533. Date of Electronic Publication: 2024 Feb 25.Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).

  • Authors : Kijak GH; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. .; Ahani B

  • Source: Infectious diseases and therapy [Infect Dis Ther] 2023 Dec; Vol. 12 (12), pp. 2691-2707. Date of Electronic Publication: 2023 Nov 02.Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.

  • Authors : Hobbs FDR; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.; Montgomery H

  • Source: Infectious diseases and therapy [Infect Dis Ther] 2023 Sep; Vol. 12 (9), pp. 2269-2287. Date of Electronic Publication: 2023 Sep 26.Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-6 ل  6 نتائج ل ""AZD7442""